58532-56-2

Usage

Uses

Used in Flavor and Fragrance Industry:
Methyl 2-(6-Methylpyridin-2-yl)acetate is utilized as a flavor and fragrance ingredient, adding a fruity scent to various products such as perfumes, soaps, and cosmetics. Its pleasant aroma and stability make it a popular choice in this industry.
Used in Pharmaceutical Manufacturing:
In the pharmaceutical sector, Methyl 2-(6-Methylpyridin-2-yl)acetate serves as a key component in the production of certain medications. Its chemical properties allow it to contribute to the development of effective drug formulations.
Used as a Solvent in Chemical Reactions:
Methyl 2-(6-Methylpyridin-2-yl)acetate is also employed as a solvent in various chemical processes. Its ability to dissolve a wide range of substances and facilitate reactions makes it a versatile tool in the chemical industry.

Upstream product

• 108-48-5 2,6-dimethylpyridine 
• 616-38-6 carbonic acid dimethyl ester 
• 896107-30-5 2-(6-methylpyridin-2-yl)malonic acid diethyl ester 
• 18107-18-1 diazomethyl-trimethyl-silane 

Relevant academic research and scientific papers

Palladium-catalyzed decarboxylative couplings of 2-(2-Azaaryl)acetates with aryl halides and triflates

Pd-catalyzed decarboxylative cross-couplings of 2-(2-azaaryl)acetates with aryl halides and triflates have been discovered. This reaction is potentially useful for the synthesis of some functionalized pyridines, quinolines, pyrazines, benzoxazoles, and benzothiazoles. Theoretical analysis shows that the nitrogen atom at the 2-position of the heteroaromatics directly coordinates to Pd(II) in the decarboxylation transition state.

N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR

The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein: each R1 is independently selected from the group consisting of Cl, Br, CH3 and CF3; X is carbon or nitrogen; R1a is H or a straight C1-3 alkyl group; R2a is H or a methyl group R2 is selected from the group consisting of C1-3alkyl, H and -(CH2)n-, wherein n is 3 or 4 and the terminal carbon of the chain is bonded to the carbon atom adjacent to the nitrogen bearing the R2 group, such that a fused 6,5 or 6,6-bicyclic ring is formed. Y is selected from the group consisting of: phenyl which may be unsubstituted or substituted by one or more substituents independently selected from the group consisting of C1-3alkyl, C1-3alkoxy, halogen, C1-3alkyl substituted by 1 to 7 fluoro atoms and C1-3alkoxy substituted by 1 to 7 fluoro atoms; pyridyl which may be unsubstituted or substituted by one or more substituents independently selected from the group consisting of C1-3alkyl, OCH3, CF3, CN, and halogen; naphthyl which may be unsubstituted or substituted by one or more substituents independently selected from the group consisting of F and OCH3; pyrimidinyl; imidazo[1,2-a]pyridine-6-yl; benzothiophen-2-yl; benzothiophen-5-yl; benzofuran-2-yl; dibenzo[b,d]furan-3-yl; dibenzo[b,d]thiophen-2-yl; dibenzo[b,d]thiophen-4-yl; 1,3- benzodioxol-5-yl; 2,3-dihydro-1,4-benzodioxin-5-yl; 2,3-dihydro-1,4-benzodioxin-6-yl; 2,3- dihydro-1-benzofuran-4-yl; 2,2-difluoro-1,3-benzodiox-4-yl; pyridazinyl; imidazolyl; oxazolyl; pyrazolyl; thiazolyl; and triazolyl; with the proviso that when Y is 2,3-dihydro-1,4-benzodioxin-6-yl, R1 is not Cl; processes for their preparation, intermediates useble in these processes, pharmaceutical compositions containing them and their use in therapy, for example as modulators of of the growth hormone secretagogue receptor (also referred to as the ghrelin receptor or GHSR1a receptor) and/or for the treatment and/or prophylaxis of a disorder mediated by the ghrelin receptor.